1. All Products
  2. RIBAVIRIN, 200mg, tab.
Public Pricelist

RIBAVIRIN, 200mg, tab.

https://msf.oodin.sh/cat/product/41040
STD DORARIBA2T-

Valid Article

Former Code(s): DORAZBD0493
6.4.4.2.3 - Other antivirals for hepatitis C
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AP01
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://msf.oodin.sh/web/image/product.template/574398/image_1920?unique=aef2dcf

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

RIBAVIRIN

Therapeutic Action

Antiviral

Indications

Aetiological treatment of Lassa fever and Crimean-Congo fever

Second-line treatment (re-treatment) of chronic hepatitis C virus (HCV) in selected countries, in combination with direct-acting antivirals (DAAs) such as sofosbuvir/velpatasvir.

Instructions for use

For the re-treatment of HCV, ribavirin should always be used in combination with a direct-acting antiviral (DAA) containing sofosbuvir, such as the combination of sofosbuvir/daclastavir.

Due to the frequent dose adjustments required to manage ribavirin-related side effects, the 200 mg concentration is preferred.

Precautions for Use

Contraindicated in patients with anaemia, severe cardiac disease, haemoglobinopathies, renal impairment

Do not administer in pregnant women (and until 5 months after delivery)

Caution!

Ribavirin is teratogenic and passes into semen. Pregnancy should be excluded before initiation treatment. Effective contraception is essential during treatment and for six months after treatment in females of childbearing age and in males sexually active. Routine monthly pregnancy tests are recommended.

Storage

Below 25ºC